146 related articles for article (PubMed ID: 22335580)
1. Targeting the epigenome in ovarian cancer.
Murphy SK
Future Oncol; 2012 Feb; 8(2):151-64. PubMed ID: 22335580
[TBL] [Abstract][Full Text] [Related]
2. Epigenomics and ovarian carcinoma.
Maldonado L; Hoque MO
Biomark Med; 2010 Aug; 4(4):543-70. PubMed ID: 20701443
[TBL] [Abstract][Full Text] [Related]
3. Targeted epigenetic therapies: the next frontier?
Tuma RS
J Natl Cancer Inst; 2010 Dec; 102(24):1824-5. PubMed ID: 21139098
[No Abstract] [Full Text] [Related]
4. Epigenetic therapy for ovarian cancer: promise and progress.
Moufarrij S; Dandapani M; Arthofer E; Gomez S; Srivastava A; Lopez-Acevedo M; Villagra A; Chiappinelli KB
Clin Epigenetics; 2019 Jan; 11(1):7. PubMed ID: 30646939
[TBL] [Abstract][Full Text] [Related]
5. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
[TBL] [Abstract][Full Text] [Related]
6. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
7. Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer.
Wrzeszczynski KO; Varadan V; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
Methods Mol Biol; 2013; 1049():35-51. PubMed ID: 23913207
[TBL] [Abstract][Full Text] [Related]
8. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
9. Epigenetics in ovarian cancer.
Seeber LM; van Diest PJ
Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
[TBL] [Abstract][Full Text] [Related]
10. The role of targeted therapy in ovarian cancer.
Banerjee S; Kaye S
Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
[TBL] [Abstract][Full Text] [Related]
11. SiRNA and epigenetic aberrations in ovarian cancer.
Mirzaei H; Yazdi F; Salehi R; Mirzaei HR
J Cancer Res Ther; 2016; 12(2):498-508. PubMed ID: 27461600
[TBL] [Abstract][Full Text] [Related]
12. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer.
Douwes F; BogoviC J; Douwes O; Migeod F; Grote C
Int J Clin Oncol; 2004 Apr; 9(2):85-91. PubMed ID: 15108039
[TBL] [Abstract][Full Text] [Related]
13. Treatment of ovarian cancer beyond chemotherapy: are we hitting the target?
Garces ÁH; Dias MS; Paulino E; Ferreira CG; de Melo AC
Cancer Chemother Pharmacol; 2015 Feb; 75(2):221-34. PubMed ID: 25212538
[TBL] [Abstract][Full Text] [Related]
14. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
15. The changing landscape of therapeutic strategies for recurrent ovarian cancer.
Baumann KH; Wagner U; du Bois A
Future Oncol; 2012 Sep; 8(9):1135-47. PubMed ID: 23030488
[TBL] [Abstract][Full Text] [Related]
16. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.
Murphy SK; Huang Z; Wen Y; Spillman MA; Whitaker RS; Simel LR; Nichols TD; Marks JR; Berchuck A
Mol Cancer Res; 2006 Apr; 4(4):283-92. PubMed ID: 16603642
[TBL] [Abstract][Full Text] [Related]
17. Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.
Zhao L; Guo H; Chen X; Zhang W; He Q; Ding L; Yang B
Eur J Pharmacol; 2022 Jul; 927():175071. PubMed ID: 35636522
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of pemetrexed in ovarian cancer.
Tomao F; Panici PB; Frati L; Tomao S
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1727-35. PubMed ID: 19954283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
